Integrated Wealth Concepts LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Integrated Wealth Concepts LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 40.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 748 shares of the biopharmaceutical company’s stock after purchasing an additional 214 shares during the period. Integrated Wealth Concepts LLC’s holdings in Regeneron Pharmaceuticals were worth $786,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Investment Management Corp of Ontario increased its stake in shares of Regeneron Pharmaceuticals by 50.3% in the 3rd quarter. Investment Management Corp of Ontario now owns 3,587 shares of the biopharmaceutical company’s stock worth $3,771,000 after purchasing an additional 1,200 shares in the last quarter. Itau Unibanco Holding S.A. increased its holdings in Regeneron Pharmaceuticals by 115.0% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 86 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 46 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Regeneron Pharmaceuticals by 76.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 23,591 shares of the biopharmaceutical company’s stock worth $24,800,000 after acquiring an additional 10,213 shares in the last quarter. Beacon Investment Advisory Services Inc. raised its stake in Regeneron Pharmaceuticals by 0.7% during the 3rd quarter. Beacon Investment Advisory Services Inc. now owns 27,186 shares of the biopharmaceutical company’s stock worth $28,579,000 after acquiring an additional 198 shares during the period. Finally, Benjamin Edwards Inc. lifted its holdings in Regeneron Pharmaceuticals by 12,448.0% during the third quarter. Benjamin Edwards Inc. now owns 3,137 shares of the biopharmaceutical company’s stock valued at $3,298,000 after purchasing an additional 3,112 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Evercore ISI cut their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,107.29.

Regeneron Pharmaceuticals Stock Up 1.3 %

Shares of REGN opened at $788.00 on Tuesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $871.59 and a 200 day moving average of $1,010.52. The company has a market cap of $86.59 billion, a PE ratio of 19.50, a P/E/G ratio of 3.00 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.